PMCB - דינמיקת הכנסות משנה לשנה ב-12 החודשים האחרונים pharmacyte.com

Year-over-year revenue dynamics for the trailing twelve months (TTM) demonstrate the current status of PharmaCyte Biotech (PMCB), where the figure remains at 0.00. PharmaCyte Biotech is developing the Cell-in-a-Box platform for live cell delivery in tumor therapy, ensuring pricing power. The company plans to generate revenue through cell encapsulation for the treatment of solid neoplasms. A unique patent creates a defensive barrier, although prolonged testing is slowing capitalization growth.

Amidst the strategic pivot of PharmaCyte Biotech (PMCB) and the freezing of early R&D tests to preserve liquidity, traditional revenue is taking a backseat. This metric measures the percentage change in sales volumes over a rolling year to smooth out quarterly fluctuations; analyzing this rolling 12-month sales volume chart against YoY figures allows investors to assess the actual resilience of the business model while the company seeks pharmaceutical partners.